Table 3.
Personal and professional reflections and attitudes towards pharmacogenomics and personal genotyping. The number and percent of individuals who agree or strongly agree with the survey question are represented within the table below. Only data from the second year is shown in the pre-educational intervention column; it was not collected in the pre-educational intervention for the first year.
| Survey Question | Overall (Pre n = 29, Post n = 69) | Genotyped (Pre n = 16, Post n = 38) | Non-Genotyped (Pre n = 13, Post n = 31) | Genotyped vs. Non-Genotyped Post | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | p Value | Pre | Post | p Value | Pre | Post | p Value | p Value | |
| I can explain the rationale for pharmacogenomic testing in various therapeutic areas to patients. | 15 (52%) | 54 (78%) | 0.0074 | 11 (69%) | 31 (82%) | 0.1172 | 4 (31%) | 23 (64%) | 0.277 | 0.3293 |
| I can identify therapeutic areas in which pharmacogenomic testing is required. | 10 (35%) | 45 (65%) | 0.0138 | 7 (44%) | 27 (71%) | 0.1445 | 3 (23%) | 18 (58%) | 0.219 | 0.2786 |
| I can identify therapeutic areas in which pharmacogenomic testing is recommended. | 13 (45%) | 52 (75%) | 0.0268 | 10 (63%) | 32 (84%) | 0.1328 | 3 (23%) | 20 (65%) | 0.969 | 0.0263 |
| I can interpret the results of pharmacogenomic testing from patients. | 9 (31%) | 33 (48%) | 0.0305 | 6 (38%) | 20 (53%) | 0.0469 | 3 (23%) | 13 (42%) | 0.912 | 0.2651 |
| The pharmacy profession should be more active in educating patients and other healthcare providers about pharmacogenomics. | 22 (76%) | 51 (74%) | 0.8516 | 13 (82%) | 31 (82%) | 1 | 9 (69%) | 20 (65%) | 0.274 | 0.0392 |